Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia -

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers | Haematological disorders
Summary
This RCT (n=326) found a higher rate of complete remission with inotuzumab ozogamicin (IO) vs standard intensive chemotherapy (80.7% vs 29.4%, p<0.001). Progression free survival was also improved with IO (5.0 vs 1.8 months respectively, p<0.001).
UKMi comment
Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody calicheamicin conjugate.
Related links: